Pushing ahead with cancer drug research, Peloton brings its latest round to $75M
Dallas-based Peloton Therapeutics has bagged an extra $22.2 million for its Series D round, bringing the total to $74.6 million.
Much of that money is being earmarked for PT2385, an early-stage drug which Peloton sees as a “first-in-class” small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor involved in cancer progression. Their lead program is currently in a Phase I study for clear cell renal cell carcinoma, or ccRCC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.